BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-0.11%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$7.97B
AUM Growth
+$7.97B
(-9.3%)
Cap. Flow
+$3.4M
Cap. Flow
% of AUM
0.04%
Top 10 Holdings %
Top 10 Hldgs %
77.13%
Holding
96
New
12
Increased
15
Reduced
7
Closed
7
Top Buys
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
$78.5M |
| 2 |
Revolution Medicines
RVMD
|
$77.4M |
| 3 |
Edgewise Therapeutics
EWTX
|
$49.7M |
| 4 |
Denali Therapeutics
DNLI
|
$23.1M |
| 5 |
Celcuity
CELC
|
$22M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$242M |
| 2 |
Immunocore
IMCR
|
$65.4M |
| 3 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
$20.9M |
| 4 |
Day One Biopharmaceuticals
DAWN
|
$14.6M |
| 5 |
ARS Pharmaceuticals
SPRY
|
$11M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sera Prognostics
SERA
$129M
| $49.5M | 0.62% |
5,434,399
| – | – |
|
27
Prelude Therapeutics
PRLD
$69.1M
| $48M | 0.6% |
10,123,824
| – | – |
|
28
IDEAYA Biosciences
IDYA
$2.26B
| $46.6M | 0.58% |
1,062,123
| – | – |
|
29
Stoke Therapeutics
STOK
$1.08B
| $45.5M | 0.57% |
3,368,443
+1,338,309
| +66% | +$18.1M |
|
30
Xenon Pharmaceuticals
XENE
$2.99B
| $42.8M | 0.54% |
993,679
| – | – |
|
|
IGMS
31
DELISTED
IGM Biosciences
IGMS
| $39.5M | 0.49% |
4,088,322
+397,311
| +11% | +$3.83M |
|
32
Cerus
CERS
$251M
| $36.8M | 0.46% |
19,477,339
| – | – |
|
33
Monte Rosa Therapeutics
GLUE
$309M
| $34.7M | 0.43% |
4,916,095
| – | – |
|
|
34
Celcuity
CELC
$2.3B
| $33.5M | 0.42% |
1,552,478
+1,017,000
| +190% | +$22M |
|
35
Biomea Fusion
BMEA
$114M
| $31.5M | 0.4% |
2,108,949
| – | – |
|
36
Krystal Biotech
KRYS
$4.35B
| $30.2M | 0.38% |
169,934
| – | – |
|
37
Sana Biotechnology
SANA
$759M
| $23.8M | 0.3% |
2,380,949
+380,949
| +19% | +$3.81M |
|
38
Neurogene
NGNE
$284M
| $23.2M | 0.29% |
456,015
+2,499
| +0.6% | +$127K |
|
|
VERV
39
DELISTED
Verve Therapeutics
VERV
| $22.5M | 0.28% |
1,691,530
| – | – |
|
40
TScan Therapeutics
TCRX
$106M
| $22.1M | 0.28% |
2,784,792
| – | – |
|
|
ADAP
41
Adaptimmune Therapeutics
ADAP
$13.9M
| $17M | 0.21% |
10,787,022
-182,260
| -2% | -$288K |
|
42
Immunovant
IMVT
$2.91B
| $13.7M | 0.17% |
425,009
| – | – |
|
|
TSVT
43
DELISTED
2seventy bio
TSVT
| $13.4M | 0.17% |
2,497,526
| – | – |
|
44
Fate Therapeutics
FATE
$115M
| $13.3M | 0.17% |
+1,818,181
| New | +$13.3M |
|
45
Xencor
XNCR
$594M
| $12.1M | 0.15% |
545,431
+300,000
| +122% | +$6.64M |
|
46
Taysha Gene Therapies
TSHA
$791M
| $11.5M | 0.14% |
4,004,756
| – | – |
|
|
DBVT
47
DBV Technologies
DBVT
$249M
| $10.9M | 0.14% |
14,614,264
| – | – |
|
48
Celldex Therapeutics
CLDX
$1.57B
| $10.4M | 0.13% |
247,644
| – | – |
|
49
Relay Therapeutics
RLAY
$709M
| $9.63M | 0.12% |
1,160,117
| – | – |
|
50
Insmed
INSM
$30.3B
| $9.31M | 0.12% |
343,000
| – | – |
|